Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death.

Visco C, Tisi MC, Evangelista A, Di Rocco A, Zoellner AK, Zilioli VR, Hohaus S, Sciarra R, Re A, Tecchio C, Chiappella A, Morello L, Gini G, Nassi L, Perrone T, Molinari AL, Fabbri A, Cox MC, Finolezzi E, Ferrero S, Puccini B, Alvarez De Celis I, Arcari A, Marino D, Merli M, Piazza F, Gentile M, Pelosini M, Loseto G, Hermine O, Dreyling M, Ruggeri M, Martelli M, Hoster E, Vitolo U; Fondazione Italiana Linfomi and the Mantle Cell Lymphoma Network.

Br J Haematol. 2018 Nov 8. doi: 10.1111/bjh.15643. [Epub ahead of print] No abstract available.

PMID:
30407625
2.

Role of bone marrow biopsy in staging of patients with classical Hodgkin's lymphoma undergoing positron emission tomography/computed tomography.

Puccini B, Nassi L, Minoia C, Volpetti S, Ciancia R, Riccomagno PC, Di Rocco A, Mulè A, Toldo C, Sassone MC, Guariglia R, Filì C, Finolezzi E, Falorio S, Zanon S, Furlan A, Doa G, Zaja F; Fondazione Italiana Linfomi Postgraduate Master course.

Ann Hematol. 2017 Jul;96(7):1147-1153. doi: 10.1007/s00277-017-2996-8. Epub 2017 Apr 28.

PMID:
28451805
3.

Combination of rituximab and nonpegylated liposomal doxorubicin (R-NPLD) as front-line therapy for aggressive non-Hodgkin lymphoma (NHL) in patients 80 years of age or older: a single-center retrospective study.

Ricciuti G, Finolezzi E, Luciani S, Ranucci E, Federico M, Di Nicola M, Zecca IAL, Angrilli F.

Hematol Oncol. 2018 Feb;36(1):44-48. doi: 10.1002/hon.2386. Epub 2017 Feb 3.

PMID:
28156055
4.

[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study.

Martelli M, Ceriani L, Zucca E, Zinzani PL, Ferreri AJ, Vitolo U, Stelitano C, Brusamolino E, Cabras MG, Rigacci L, Balzarotti M, Salvi F, Montoto S, Lopez-Guillermo A, Finolezzi E, Pileri SA, Davies A, Cavalli F, Giovanella L, Johnson PW.

J Clin Oncol. 2014 Jun 10;32(17):1769-75. doi: 10.1200/JCO.2013.51.7524. Epub 2014 May 5.

PMID:
24799481
5.

Identification of pharmacogenomic markers of clinical efficacy in a dose-dense therapy regimen (R-CHOP14) in diffuse large B-cell lymphoma.

Nobili S, Napoli C, Puccini B, Landini I, Perrone G, Brugia M, Benelli G, Doria M, Martelli M, Finolezzi E, Di Rocco A, Del Fava E, Rigacci L, Di Lollo S, Bosi A, Mini E.

Leuk Lymphoma. 2014 Sep;55(9):2071-8. doi: 10.3109/10428194.2013.866665. Epub 2014 Feb 24.

PMID:
24289107
6.

Prospective phase II single-center study of the safety of a single very high dose of liposomal amphotericin B for antifungal prophylaxis in patients with acute myeloid leukemia.

Annino L, Chierichini A, Anaclerico B, Finolezzi E, Norata M, Cortese S, Cassetta MI, Fallani S, Novelli A, Girmenia C.

Antimicrob Agents Chemother. 2013 Jun;57(6):2596-602. doi: 10.1128/AAC.00155-13. Epub 2013 Mar 25.

7.

Atypical presentation of anaplastic large T-cell lymphoma mimicking an articular relapse of rheumatoid arthritis in a patient treated with etanercept. A case report and literature review.

De Angelis F, Di Rocco A, Minotti C, Valesini G, Cartoni C, Riminucci M, Conti F, Finolezzi E, Armiento D, Grammatico S, Massaro L, Fama A, Colafigli G, Viccarone C, Foà R, Martelli M.

Leuk Res. 2012 Sep;36(9):e199-201. doi: 10.1016/j.leukres.2012.06.004. Epub 2012 Jun 30. Review. No abstract available. Erratum in: Leuk Res. 2013 Oct;37(10):1393.

PMID:
22749557
8.

Behind the scenes of non-nodal MCL: downmodulation of genes involved in actin cytoskeleton organization, cell projection, cell adhesion, tumour invasion, TP53 pathway and mutated status of immunoglobulin heavy chain genes.

Del Giudice I, Messina M, Chiaretti S, Santangelo S, Tavolaro S, De Propris MS, Nanni M, Pescarmona E, Mancini F, Pulsoni A, Martelli M, Di Rocco A, Finolezzi E, Paoloni F, Mauro FR, Cuneo A, Guarini A, Foà R.

Br J Haematol. 2012 Mar;156(5):601-11. doi: 10.1111/j.1365-2141.2011.08962.x. Epub 2011 Dec 8.

PMID:
22150124
9.

New category of probable invasive pulmonary aspergillosis in haematological patients.

Girmenia C, Guerrisi P, Frustaci AM, Fama A, Finolezzi E, Perrone S, Gentile G, Collerone F, Brocchieri S, Guerrisi V.

Clin Microbiol Infect. 2012 Oct;18(10):990-6. doi: 10.1111/j.1469-0691.2011.03685.x. Epub 2011 Oct 17.

10.

Impact of dose-dense immunochemotherapy on prognosis of germinal center and non germinal center origin of diffuse large B cell lymphoma.

Rigacci L, Puccini B, Iovino L, Martelli M, Finolezzi E, DI Lollo S, Doria M, Bosi A.

J Chemother. 2011 Aug;23(4):227-31.

PMID:
21803701
11.

Invasive Candida infections in patients with haematological malignancies and hematopoietic stem cell transplant recipients: current epidemiology and therapeutic options.

Girmenia C, Finolezzi E, Federico V, Santopietro M, Perrone S.

Mediterr J Hematol Infect Dis. 2011;3(1):e2011013. doi: 10.4084/MJHID.2011.013. Epub 2011 Mar 15.

12.

Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.

Zinzani PL, Stefoni V, Finolezzi E, Brusamolino E, Cabras MG, Chiappella A, Salvi F, Rossi A, Broccoli A, Martelli M.

Clin Lymphoma Myeloma. 2009 Oct;9(5):381-5. doi: 10.3816/CLM.2009.n.074.

PMID:
19858058
13.

MACOP-B and involved-field radiotherapy is an effective and safe therapy for primary mediastinal large B cell lymphoma.

De Sanctis V, Finolezzi E, Osti MF, Grapulin L, Alfò M, Pescarmona E, Berardi F, Natalino F, Moleti ML, Di Rocco A, Enrici RM, Foà R, Martelli M.

Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1154-60. doi: 10.1016/j.ijrobp.2008.02.036. Epub 2008 May 9.

PMID:
18472357
14.

Rituximab associated to imatinib for coexisting therapy-related chronic myeloid leukaemia and relapsed non-Hodgkin lymphoma.

Breccia M, Martelli M, Cannella L, Russo E, Finolezzi E, Stefanizzi C, Levi A, Frustaci A, Alimena G.

Leuk Res. 2008 Feb;32(2):353-5. Epub 2007 Sep 7.

PMID:
17825907
15.

Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia.

Cimino G, Lo-Coco F, Fenu S, Travaglini L, Finolezzi E, Mancini M, Nanni M, Careddu A, Fazi F, Padula F, Fiorini R, Spiriti MA, Petti MC, Venditti A, Amadori S, Mandelli F, Pelicci PG, Nervi C.

Cancer Res. 2006 Sep 1;66(17):8903-11.

16.

The role of BCR/ABL isoforms in the presentation and outcome of patients with Philadelphia-positive acute lymphoblastic leukemia: a seven-year update of the GIMEMA 0496 trial.

Cimino G, Pane F, Elia L, Finolezzi E, Fazi P, Annino L, Meloni G, Mancini M, Tedeschi A, Di Raimondo F, Specchia G, Fioritoni G, Leoni P, Cuneo A, Mecucci C, Saglio G, Mandelli F, Foà R; GIMEMA Leukemia Working Party.

Haematologica. 2006 Mar;91(3):377-80.

17.

[Therapeutic advances in neoplastic hematology: target therapy anti-CD33].

Di Rocco A, Finolezzi E, Anaclerico B, Calabrese E, Levi A, Trasarti S, Tafuri A.

Clin Ter. 2005 Jul-Aug;156(4):183-6. Review. Italian.

PMID:
16342520
18.

Systematic radical gastrectomy and D2 lymphadenectomy in primary gastric B cell lymphoma: impact on diagnosis, classification and long term results. A prospective study.

Caronna R, Cardi M, Martelli M, Finolezzi E, Natalino F, Mingazzini P, Scozzafava S, Mangioni S, Romeo BG, Tarantino E, Benedetti M, Pittau G, Schiratti M, Chirletti P.

J Chemother. 2004 Nov;16 Suppl 5:26-9.

PMID:
15675472
19.

Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia.

Lo-Coco F, Cimino G, Breccia M, Noguera NI, Diverio D, Finolezzi E, Pogliani EM, Di Bona E, Micalizzi C, Kropp M, Venditti A, Tafuri A, Mandelli F.

Blood. 2004 Oct 1;104(7):1995-9. Epub 2004 Jun 8.

20.

Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia.

Carmosino I, Latagliata R, Avvisati G, Breccia M, Finolezzi E, Lo Coco F, Petti MC.

Haematologica. 2004 May;89(5):615-7.

21.

[Anthracycline cardiotoxicity].

Finolezzi E, Torromeo C, Vincenzi B, Avvisati G.

Clin Ter. 2003 Mar-Apr;154(2):115-21. Review. Italian.

PMID:
12856371
22.

Prevention of radiotherapy-induced emesis.

Tonini G, Vincenzi B, Santini D, La Cesa A, Finolezzi E, Onori N, D'Angelillo R, Baldi A, Trodella L.

J Exp Clin Cancer Res. 2003 Mar;22(1):17-22. Review.

PMID:
12725317
23.

Relevance of CD79a expression for T-cell lineage attribution in CD7+/CD3- acute lymphoblastic leukemia.

Finolezzi E, Corral L, Martelli MP, De Propris MS, Falini B, Cimino G.

Haematologica. 2002 Oct;87(10):ELT41. No abstract available.

PMID:
12368180
24.

Raltitrexed as monochemotherapy induces a statistically significant increase in platelet count.

Tonini G, Santini D, Vincenzi B, Dicuonzo G, Salerno A, Finolezzi E, Avvisati G.

Acta Oncol. 2002;41(3):315-6. No abstract available.

PMID:
12195753
25.

The antineoplastic treatment in the elderly.

Vincenzi B, Santini D, Spoto S, Finolezzi E, D'Angelillo RM, La Cesa A, Tonini G.

Clin Ter. 2002 May-Jun;153(3):207-15. Review.

PMID:
12161983
26.

Unusual presentation of Hodgkin's disease mimicking inflammatory bowel disease.

Vincenzi B, Finolezzi E, Fossati C, Verzì A, Santini D, Tonini G, Arullani A, Avvisati G.

Leuk Lymphoma. 2001 Jul;42(3):521-6.

PMID:
11699419
27.

[The prevention of vomiting due to antineoplastic chemotherapy in the elderly cancer patient].

Santini D, Vincenzi B, Finolezzi E, Di Cosimo S, Gravante G, Spoto S, Tonini G.

Minerva Med. 1999 Jul-Aug;90(7-8):205-9. Review. Italian. No abstract available.

PMID:
10719419

Supplemental Content

Loading ...
Support Center